STAT3 and neoplasm: However, neither STAT3 activation nor anti-tumor activity of IL-6 antibody CNTO328 was observed in our HCC4006ER cells, suggesting that the IL-6/STAT3 pathway is not necessarily activated in EMT-related acquired EGFR-TKI resistance in NSCLC.